403 related articles for article (PubMed ID: 34554395)
1. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
2.
Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
[TBL] [Abstract][Full Text] [Related]
3. Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation.
Das SK; Mahanta S; Tanti B; Tag H; Hui PK
Mol Divers; 2022 Feb; 26(1):365-388. PubMed ID: 33961167
[TBL] [Abstract][Full Text] [Related]
4. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
6. Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach.
Rajagopal K; Sri VB; Byran G; Gomathi S
Curr Drug Res Rev; 2022; 14(1):61-72. PubMed ID: 34139975
[TBL] [Abstract][Full Text] [Related]
7. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
9. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
11. Identification of luteolin -7-glucoside and epicatechin gallate from
Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
[TBL] [Abstract][Full Text] [Related]
13. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
14. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
15. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
[TBL] [Abstract][Full Text] [Related]
16.
Maruthanila VL; Elancheran R; Mirunalini S
Curr Comput Aided Drug Des; 2022; 18(3):196-212. PubMed ID: 35598239
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
[TBL] [Abstract][Full Text] [Related]
18. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors.
Gogoi D; Baruah VJ; Chaliha AK; Kakoti BB; Sarma D; Buragohain AK
J Theor Biol; 2016 Dec; 411():68-80. PubMed ID: 27693363
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics.
Ahmad Ansari I; Debnath B; Kar S; Patel HM; Debnath S; Zaki MEA; Pal P
J Biomol Struct Dyn; 2024 Mar; 42(5):2464-2481. PubMed ID: 37349948
[TBL] [Abstract][Full Text] [Related]
20. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
